Dissociation and acute neuropsychiatric effect monitoring

The manuals converge on close monitoring of acute altered states after ketamine, ayahuasca, psilocybin, ibogaine, or related interventions, with repeated attention to dissociation, psychosis-like symptoms, agitation, confusion, and manic activation. Across the extracts, these experiences are treated as observable safety signals that are tracked during the dosing or intoxication window, then documented and followed over time if they become clinically significant. They also agree that structured assessment matters. Several sources describe clinician-rated or repeated time-point measures, alongside direct observation and participant report, to distinguish expected transient psychedelic effects from deterioration that needs escalation. Some manuals explicitly mention adverse event documentation, emergency support, or post-session observation and discharge readiness, showing a shared concern with safety surveillance beyond the peak acute phase. The manuals differ in emphasis and setting. Ketamine protocols place more weight on psychosis-like symptoms, mania, suicidality, and emergency management during infusion or post-treatment monitoring, while ayahuasca and psilocybin sources focus more on altered states, dissociation, and acute psychedelic intensity during the session. Ibogaine guidance is more centred on delirium and psychomimetic effects, and some manuals extend into discharge criteria and longer observation periods, whereas others focus mainly on repeated symptom ratings during the dosing session.